We found that PD-L1 expression lower than 1% in tumor and immune cells, a line of immunotherapeutic treatment other than the first line, an acral lentiginous histological melanoma subtype, and an anti-CTLA-4 treatment as monotherapy were associated with poor responses (Table 1). Here, CTLA4 is linked to neoplasm.